DOJ accuses Louisiana AG, alleged victim of abortion coercion of trying to "short circuit" FDA's review of mifepristone's ...
9don MSNOpinion
You Say The Supreme Court Isn’t Partisan? Look in the Shadow
This article is part of TPM Cafe, TPM’s home for opinion and news analysis. As the Supreme Court wrapped ...
The Supreme Court on Jan. 16, 2026, agreed to decide a case about how generic companies can communicate to the market about their products, ...
On January 12, 2026, the Delaware Supreme Court issued an en banc opinion in Johnson & Johnson v. Fortis Advisors LLC, No.
WASHINGTON, Jan 16 (Reuters) - The U.S. Supreme Court agreed on Friday to hear a patent dispute involving Amarin Pharma's ...
On Friday, the U.S. Supreme Court granted certiorari to a petition filed by patent owner Hikma Pharmaceuticals, taking up ...
The U.S. Supreme Court has decided to hear a case between Amarin Pharma and generic drugmaker Hikma that puts so-called ...
Many drugmakers are participating in a speedier FDA review program introduced by the Trump administration, but some companies ...
At a Glance The FDA reversed its 2022 NMN ban in September 2025, allowing the $500 million ingredient back on the market ...
A systematic review found that FDA leaders historically accepted recommendations made by the agency’s scientists regarding mifepristone.
The U.S. Supreme Court will hear oral arguments on Tuesday in a case over whether states can prevent concealed carry holders ...
Shares of Bayer AG BAYRY gained 6.41% on Jan. 19, after the company announced that the Supreme Court agreed to review the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results